A5103076342- Gastrointestinal Tumor Research and Treatment
- Ear and Head Tumors
- Cancer-related gene regulation
- Sarcoma Diagnosis and Treatment
- Lung Cancer Diagnosis and Treatment
- Cancer-related molecular mechanisms research
- Nerve injury and regeneration
- Platelet Disorders and Treatments
- Immunodeficiency and Autoimmune Disorders
- Uterine Myomas and Treatments
- Salivary Gland Tumors Diagnosis and Treatment
- Pleural and Pulmonary Diseases
- Infectious Diseases and Mycology
- Occupational and environmental lung diseases
- Monoclonal and Polyclonal Antibodies Research
- Oral and Maxillofacial Pathology
- Immune Cell Function and Interaction
- Gastric Cancer Management and Outcomes
- Cancer Immunotherapy and Biomarkers
- Mesenchymal stem cell research
- Wound Healing and Treatments
- Ovarian cancer diagnosis and treatment
- Gastrointestinal disorders and treatments
- Renal cell carcinoma treatment
- Reconstructive Surgery and Microvascular Techniques
Mayo Clinic in Arizona
2020-2024
The Ohio State University
2012-2017
Emory University
2013-2017
Grady Memorial Hospital
2016
The Ohio State University Wexner Medical Center
2013
BACKGROUND Human papillomavirus 16 (HPV16) is a major risk factor for the development of head and neck squamous cell carcinoma (HNSCC), particularly oropharyngeal (OPSCC). Cancer stem cells (CSCs) are resistant to conventional therapies, it postulated that they responsible disease recurrence and/or progression. Because prognoses patients with HPV16‐positive HPV‐negative HNSCC distinct, authors sought determine whether differences in number CSCs could account this clinical observation....
// Bhavna Kumar 1, 2 , Arti Yadav Nicole V. Brown 3 Songzhu Zhao Michael J. Cipolla 1 Paul E. Wakely 4 Alessandra C. Schmitt 4, 6 Robert A. Baiocchi 5 Theodoros N. Teknos Matthew Old 2, * Pawan Department of Otolaryngology-Head and Neck Surgery, The Ohio State University, Columbus, OH 43210 USA University Comprehensive Cancer Center, Center for Biostatistics, Pathology, Internal Medicine, Pathology Laboratory Emory School Atlanta, GA 30303 These authors contributed equally to this work...
Optimally effective antitumor therapies would not only activate immune effector cells but also engage them at the tumor. Folate conjugated to immunoglobulin (F-IgG) could direct innate with Fc receptors folate receptor-expressing cancer cells. F-IgG bound human KB and HeLa cells, as well murine L1210JF, a receptor (FR)-overexpressing cell line, determined by flow cytometry. Recognition of natural killer (NK) led phosphorylation ERK transcription factor increased NK expression CD69. Lysis...
Gastrointestinal stromal tumors (GIST) usually occur within the bowel wall, and most contain KIT - or PDGFRA activating mutations. The routine diagnosis of GIST relies on C-kit immunohistochemical detection; however, up to 15% GISTs are negative. Antibodies with increased sensitivity specificity in detection C-kit–negative cases could be value because these also benefit from imatinib mesylate therapy. We investigated two DOG-1 antibody clones, SP31 K9, determine which would more useful GIST....
Wound healing is an intricate process involving multiple cells and distinct phases, presenting challenges for comprehensive investigations. Currently available treatments wounds have limited capacity to fully restore tissue often require significant investments of time in the form repetitive dressing changes and/or reapplications. This article presents a novel study that aims enhance wound by developing biomaterial scaffolds using Medpor®, porous polyethylene implant, as model scaffold. The...
The risk of malignancy (ROM) remains an area interest for further evaluation in reporting systems including International System serous fluid cytopathology (TIS), which is a standardized system effusion cytology. Herein, we report our findings investigation ROM TIS by studying on paired pleural specimens and corresponding biopsies with emphasis negative malignancy, atypia undetermined significance categories.
Gastrointestinal stromal tumors (GIST) usually occur within the bowel wall, and most contain KIT - or PDGFRA activating mutations. The routine diagnosis of GIST relies on C-kit immunohistochemical detection; however, up to 15% GISTs are negative. Antibodies with increased sensitivity specificity in detection C-kit–negative cases could be value because these also benefit from imatinib mesylate therapy. We investigated two DOG-1 antibody clones, SP31 K9, determine which would more useful GIST....